Blue Chip Marketing Worldwide Accelerates Patient Enrollment for Orexigen Therapeutics, Inc. (OREX) Contrave® Light Study
12/21/2012 9:03:10 AM
NORTHBROOK, Ill.--(BUSINESS WIRE)--Blue Chip Patient Recruitment (BCPR), a division of Blue Chip Marketing Worldwide, a full-service integrated marketing agency, has successfully partnered with Orexigen® Therapeutics (Nasdaq: OREX) to accelerate patient enrollment of The Light Study, Orexigen’s cardiovascular outcomes trial evaluating Contrave® (naltrexone sustained release (SR)/bupropion SR). Approximately 9,000 patients will be randomized in the study within the next few weeks, nearly 14 months ahead of original forecasts. Contrave is an investigational medication being evaluated for the treatment of obesity.